Insider Transactions Reported by 23 Insiders of
Candel Therapeutics, Inc.
-
Symbol
-
CADL on Nasdaq
-
Location
-
Needham, MA
Quick Takeaways
- CADL - Candel Therapeutics, Inc. has 23 insiders with reported activity on this page.
- Net insider value flow over the last year: +$2,989,520.
- Recent transaction rows are available for direct filing-level review.
What Changed
- Buy value: $2,999,996; sell value: $10,476.
- Net share flow: <span class="text-green-600">+548,740</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Filed on Form 4
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
See Original Filing
Insiders trading volume in the past year
Insider trading buckets (0-12 months)
Candel Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name |
Relationship |
Holdings Value |
Past Year Net Change |
Change % |
Valuation |
Report Date |
| Estuardo Aguilar-Cordova |
10%+ Owner |
$52,549,421 |
|
|
Mixed |
21 Feb 2025 |
| Paul B. Manning |
Director |
$33,268,209 |
+$2,999,996 |
+9.9% |
Mixed |
31 Mar 2026 |
| Christopher Martell |
Director |
$2,902,260 |
|
|
Mixed |
25 Jun 2025 |
| Laura K. Aguilar |
10%+ Owner |
$2,742,246 |
|
|
Mixed |
06 May 2022 |
| Paul Peter Tak |
Chief Executive Officer, Director |
$1,254,203 |
|
|
Mixed |
26 Jan 2026 |
| Joseph C. Papa |
Director |
$508,031 |
|
|
Mixed |
31 Mar 2026 |
| Francesca Barone |
Chief Scientific Officer |
$470,778 |
|
|
Mixed |
26 Jan 2026 |
| Seshu Tyagarajan |
Chief Technology Officer |
$424,339 |
|
|
Mixed |
26 Jan 2026 |
| William Garrett Nichols |
Chief Medical Officer |
$366,401 |
-$10,477 |
-2.8% |
Filing P/S |
26 Jan 2026 |
| Charles Schoch |
Chief Financial Officer |
$202,635 |
|
|
Mixed |
26 Jan 2026 |
| Jason Amello |
Chief Financial Officer |
$181,808 |
|
|
Mixed |
28 Nov 2023 |
| Udi Meirav |
Director |
$43,940 |
|
|
Mixed |
26 Jul 2021 |
| SMITH ALAN E |
Director |
$29,293 |
|
|
Mixed |
26 Jul 2021 |
| Gary J. Nabel |
Director |
$24,998 |
|
|
Mixed |
25 Jun 2025 |
| Nicoletta Loggia |
Director |
$9,998 |
|
|
Mixed |
31 Mar 2026 |
| Nathan Caffo |
Chief Business Officer |
$5,400 |
|
|
Mixed |
29 Jul 2021 |
| Renee Gaeta |
Director |
|
|
|
Mixed |
17 Jun 2025 |
| Diem Nguyen |
Director |
|
|
|
Mixed |
17 Jun 2025 |
| Maha Radhakrishnan |
Director |
|
|
|
Mixed |
04 Jun 2025 |
| Susan B. Stewart |
Chief Regulatory Officer |
|
|
|
Mixed |
11 Apr 2022 |
| Edward J. Benz Jr. |
Director |
|
|
|
Mixed |
17 Jun 2025 |
| John J. Canepa |
Chief Financial Officer |
|
|
|
Mixed |
28 Feb 2022 |
| Shaan-Chirag C. Gandhi |
Director |
|
|
|
Mixed |
26 Jul 2021 |
Recent Insider Transactions by Companies or Individuals for Candel Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider |
Symbol |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares Owned |
Date |
Ownership |
| Paul B. Manning |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
4,618 |
4,618 |
31 Mar 2026 |
Direct |
| Joseph C. Papa |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
2,795 |
2,795 |
31 Mar 2026 |
Direct |
| Nicoletta Loggia |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
779 |
779 |
31 Mar 2026 |
Direct |
| Paul B. Manning |
CADL |
Common Stock |
Purchase |
24.9% |
$2,999,996 |
$5.45 |
550,458 |
2,763,527 |
23 Feb 2026 |
By Paul B. Manning Revocable Trust |
| Seshu Tyagarajan |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
154,000 |
154,000 |
26 Jan 2026 |
Direct |
| Charles Schoch |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
232,000 |
232,000 |
26 Jan 2026 |
Direct |
| Paul Peter Tak |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
629,000 |
629,000 |
26 Jan 2026 |
Direct |
| Francesca Barone |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
232,000 |
232,000 |
26 Jan 2026 |
Direct |
| William Garrett Nichols |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
136,500 |
136,500 |
26 Jan 2026 |
Direct |
| William Garrett Nichols |
CADL |
Common Stock |
Sale |
-1.75% |
$6,540 |
$6.98 |
-937 |
52,493 |
28 Jul 2025 |
Direct |
| William Garrett Nichols |
CADL |
Common Stock |
Options Exercise |
1.78% |
|
|
937 |
53,430 |
28 Jul 2025 |
Direct |
| William Garrett Nichols |
CADL |
Stock Option (Right to Buy) |
Options Exercise |
-3.09% |
|
|
-937 |
29,377 |
28 Jul 2025 |
Direct |
| William Garrett Nichols |
CADL |
Common Stock |
Sale |
-1.47% |
$3,936 |
$5.04 |
-781 |
52,493 |
30 Jun 2025 |
Direct |
| William Garrett Nichols |
CADL |
Common Stock |
Options Exercise |
1.49% |
|
|
781 |
53,274 |
30 Jun 2025 |
Direct |
| William Garrett Nichols |
CADL |
Stock Option (Right to Buy) |
Options Exercise |
-2.51% |
|
|
-781 |
30,314 |
30 Jun 2025 |
Direct |
| Seshu Tyagarajan |
CADL |
Common Stock |
Award |
6.26% |
|
|
5,353 |
90,865 |
25 Jun 2025 |
Direct |
| Paul Peter Tak |
CADL |
Common Stock |
Award |
19% |
|
|
42,826 |
268,566 |
25 Jun 2025 |
Direct |
| Paul B. Manning |
CADL |
Common Stock |
Award |
93.7% |
|
|
1,070,663 |
2,213,069 |
25 Jun 2025 |
By Paul B. Manning Revocable Trust |
| Christopher Martell |
CADL |
Common Stock |
Award |
|
|
|
111,349 |
111,349 |
25 Jun 2025 |
By Spouse |
| Nicoletta Loggia |
CADL |
Common Stock |
Award |
|
|
|
2,141 |
2,141 |
25 Jun 2025 |
Direct |
| Charles Schoch |
CADL |
Common Stock |
Award |
14.1% |
|
|
5,353 |
43,391 |
25 Jun 2025 |
Direct |
| Gary J. Nabel |
CADL |
Common Stock |
Award |
|
|
|
5,353 |
5,353 |
25 Jun 2025 |
Direct |
| Francesca Barone |
CADL |
Common Stock |
Award |
4.44% |
|
|
4,282 |
100,809 |
25 Jun 2025 |
Direct |
| Joseph C. Papa |
CADL |
Common Stock |
Award |
|
|
|
64,239 |
64,239 |
25 Jun 2025 |
By Joseph C. Papa Revocable Living Trust |
| Charles Schoch |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
50,000 |
50,000 |
20 Jun 2025 |
Direct |
| Edward J. Benz Jr. |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Renee Gaeta |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Nicoletta Loggia |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Paul B. Manning |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Christopher Martell |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Gary J. Nabel |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Diem Nguyen |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Joseph C. Papa |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
14,240 |
14,240 |
17 Jun 2025 |
Direct |
| Maha Radhakrishnan |
CADL |
Stock Option (Right to Buy) |
Award |
|
|
|
28,480 |
28,480 |
04 Jun 2025 |
Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.